Annual Meeting of the American Thyroid Association (ATA)

Memorial Sloan Kettering Cancer Center’s experience shows that selected patients with low-risk papillary thyroid cancer can safely defer surgery in favor of active surveillance.

In this interview we discuss which distant metastases in thyroid cancer are appropriate targets for I-131 treatment, appropriate dosing, and more.

Dual inhibition of PI3K signaling and histone deacetylase 2 (HDAC2) enzymes with CUDC-907 slowed thyroid tumor cell proliferation, tumor progression and metastasis, according to a preclinical study.

Mitochondrial glycerophosphate dehydrogenase (mGPDH) is overexpressed in differentiated thyroid cancer (DTC) tissue, and metformin, which downregulates mGPDH, is associated with slowed growth in metastatic DTC tumors in mice.

The risk of immunotherapy-related destructive thyroiditis requires close patient monitoring and can cause permanent hypothyroidism.

Five years after treatment, low-dose postsurgical radioiodine (I-131) ablation for low-risk thyroid cancer offers outcomes equivalent to those seen following higher-dose ablation, according to a long-term follow-up analysis by French researchers.

As part of our coverage of the 2016 American Thyroid Association Annual Meeting we discuss active surveillance vs immediate lobectomy or thyroidectomy in papillary thyroid microcarcinoma.

A MALDI-TOF mass spectrometry (MassARRAY) mutation-detection panel shows promise for improving the presurgical diagnosis of thyroid cancers with fine needle aspirations, according to a pilot study.

In this interview on medullary thyroid carcinoma we discuss treatment strategies, prognostic biomarkers, surveillance following treatment, and more.

High-risk ultrasound findings strongly indicate that thyroid nodules are malignant, even when nodules are cytologically indeterminate following find needle aspiration.

A Japanese study found that weekly paclitaxel was safe and well-tolerated among patients with anaplastic thyroid carcinoma, a notoriously aggressive malignancy.

Immune checkpoint inhibitor therapy is looking increasingly plausible as a potential investigative strategy for treating thyroid cancers.

The coexistence of mutations in telomerase reverse transcriptase (TERT) and BRAF genes dramatically increases the risk of thyroid cancer aggressiveness, tumor recurrence and thyroid cancer-specific deaths.

Researchers in Germany appear to have identified a gene-expression signature associated with metastasis in sporadic medullary thyroid cancer and prognostic molecular tumor markers of medullary thyroid cancer response to vandetanib therapy.

New ATA Guidelines offer clear and welcome guidance against routine post-thyroidectomy remnant tumor ablation with radioactive iodine, agreed experts at the 85th Annual Meeting of the ATA.

For patients who can tolerate aggressive multimodal therapy for anaplastic thyroid carcinoma, survival rates can exceed historical outcomes, according to a retrospective study of patients treated at the Mayo Clinic.

It is too soon to determine the influence of radiation exposure on thyroid cancer risk among children and adolescents exposed to the 2011 Fukushima Daiichi nuclear power plant disaster in Japan, according to the lead author of findings presented at the 85th Annual Meeting of the ATA.

Release of newly revised, evidence-based clinical management guidelines for thyroid nodules and differentiated thyroid cancers were announced at the 85th Annual Meeting of the ATA.

Preclinical findings suggest that autophagy inhibition might prove useful in overcoming BRAF-mutant thyroid cancers resistant to vemurafenib.

The FAM83F protein contributes to papillary thyroid cancer cell viability and doxorubicin resistance, according to a study presented at the 85th Annual Meeting of the ATA.